Insmed (INSM) Q2 2024 earnings summary

Executive summary

• Achieved record quarterly revenues of $90.3 million in Q2 2024, up 17% year-over-year, driven by ARIKAYCE growth in all regions.

• Successfully raised $713.2 million in equity, ending the quarter with $1.25 billion in cash and cash equivalents.

• Positive topline Phase 3 ASPEN study results for brensocatib in bronchiectasis, with NDA filing planned for Q4 2024 and U.S. launch readiness targeted for mid-2025.

• Net loss for Q2 2024 was $300.6 million ($1.94/share), compared to $244.8 million in Q2 2023.

• Reiterated 2024 global ARIKAYCE revenue guidance of $340–$360 million, reflecting double-digit growth.

Financial highlights

• Global net revenues reached $90.3 million, a 17% increase year-over-year, with U.S. revenue at $63.8 million (+11%), Japan at $21.1 million (+35%), and Europe/ROW at $5.4 million (+37%).

• Cash and cash equivalents rose to $1,246.8 million as of June 30, 2024, primarily from equity raise and stock option exercises.

• Underlying cash burn for the quarter was $139 million, consistent with historical trends.

• Cost of product revenues was $21 million (23.2% of revenues); R&D expenses were $146.7 million, SG&A $106.6 million.

• Net loss for Q2 2024 was $300.6 million; operating loss was $288.9 million.

Outlook and guidance

• Brensocatib NDA filing planned for Q4 2024, with U.S. launch targeted for mid-2025 and European/Japanese launches in H1 2026.

• ENCORE trial topline data for ARIKAYCE expected in Q1 2026; positive results may support label expansion and full approval.

• Phase 2 readouts for brensocatib in CRS without nasal polyps and TPIP in PAH expected in 2025; Phase 3 TPIP in PH-ILD to begin in 2025.

• Over 80% of expenditures expected for mid- to late-stage and commercial programs; less than 20% for early-stage research.

• Sufficient funds to meet financial needs for at least the next 12 months; may opportunistically raise additional capital.